Other
Desmopressin
Also called DDAVP
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US and EU.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 0.33mg/mL
- Volume per draw
- 0mL
- Units to dial
- 0
- Doses per cartridge
- 0
Requested 0.003 mL
Requested 0.3
This is under the smallest 1-unit click, so the device cannot deliver it. More water lowers the concentration and makes the setting larger.
Vial label
Copy this into your label printer.
Published research contexts for Desmopressin describe 1–4 mcg per administration. Descriptive only, not a recommendation.
Terminal plasma half-life about 2–3 h, though the antidiuretic effect outlasts the measured blood level.
Desmopressin (DDAVP), a synthetic analog of the antidiuretic hormone vasopressin acting at the V2 receptor, licensed as a medicine in the US and EU. It is supplied by several routes — a subcutaneous or intravenous injection, an oral tablet and a nasal spray — and the mass differs sharply between them because little of an oral or nasal dose reaches circulation: the parenteral amount is only about 1–4 mcg, against roughly 100–400 mcg oral and 10–40 mcg nasal. The schedule below is the subcutaneous route.
Dosing schedule
How Desmopressin is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Parenteral routeThe injectable amount is far smaller than the oral (~100–400 mcg) or nasal (~10–40 mcg) routes, since little of those reaches circulation. | 1–4 mcg | Once or twice daily | SubQ |
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.07× single dose
- Time to steady state
- 15hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Mannucci PM et al., Lancet 1977 (DDAVP)The deamino-D-arginine vasopressin analog raised factor VIII and von Willebrand factor after a single dose; a V2-receptor agonist licensed across central diabetes insipidus, nocturnal polyuria and bleeding-disorder indications.